Cholangiocarcinoma (CCA) and Other Advanced Solid Tumors research hub

A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

This study is testing a new medicine, RLY-4008, for people with advanced cancers, especially a type of liver cancer called cholangiocarcinoma. It's looking to see how safe the medicine is, what dose works best, and if it can shrink tumors or stop them from growing.